234 related articles for article (PubMed ID: 11413298)
1. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.
Boyer PL; Gao HQ; Clark PK; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2001 Jul; 75(14):6321-8. PubMed ID: 11413298
[TBL] [Abstract][Full Text] [Related]
2. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.
Sarafianos SG; Das K; Clark AD; Ding J; Boyer PL; Hughes SH; Arnold E
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10027-32. PubMed ID: 10468556
[TBL] [Abstract][Full Text] [Related]
5. Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.
Halvas EK; Svarovskaia ES; Freed EO; Pathak VK
J Virol; 2000 Jul; 74(14):6669-74. PubMed ID: 10864683
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
Duan C; Poticha D; Stoeckli TC; Petropoulos CJ; Whitcomb JM; McHenry CS; Kuritzkes DR
J Infect Dis; 2001 Nov; 184(10):1336-40. PubMed ID: 11679926
[TBL] [Abstract][Full Text] [Related]
7. Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis.
Julias JG; Boyer PL; McWilliams MJ; Alvord WG; Hughes SH
Virology; 2004 Apr; 322(1):13-21. PubMed ID: 15063112
[TBL] [Abstract][Full Text] [Related]
8. Investigating the "steric gate" of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by targeted insertion of unnatural amino acids.
Klarmann GJ; Eisenhauer BM; Zhang Y; Gotte M; Pata JD; Chatterjee DK; Hecht SM; Le Grice SF
Biochemistry; 2007 Feb; 46(8):2118-26. PubMed ID: 17274599
[TBL] [Abstract][Full Text] [Related]
9. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
10. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
11. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.
Wakefield JK; Jablonski SA; Morrow CD
J Virol; 1992 Nov; 66(11):6806-12. PubMed ID: 1383571
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
14. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD
J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.
Feng JY; Anderson KS
Biochemistry; 1999 Jul; 38(29):9440-8. PubMed ID: 10413520
[TBL] [Abstract][Full Text] [Related]
16. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.
Hertogs K; Bloor S; De Vroey V; van Den Eynde C; Dehertogh P; van Cauwenberge A; Stürmer M; Alcorn T; Wegner S; van Houtte M; Miller V; Larder BA
Antimicrob Agents Chemother; 2000 Mar; 44(3):568-73. PubMed ID: 10681319
[TBL] [Abstract][Full Text] [Related]
17. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of dioxolane nucleosides against 3TC resistant M184V mutant HIV.
Chong Y; Chu CK
Antiviral Res; 2004 Jul; 63(1):7-13. PubMed ID: 15196815
[TBL] [Abstract][Full Text] [Related]
19. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1.
Quan Y; Gu Z; Li X; Li Z; Morrow CD; Wainberg MA
J Virol; 1996 Aug; 70(8):5642-5. PubMed ID: 8764080
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
García-Lerma JG; Nidtha S; Heneine W
J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
